Interestingly, the serum levels of ADAM6 in CD22+ patients were found to be significantly lower compared to CD22− ALL patients (p = 0.0427, Fig. 4A) as well as being significantly lower in CD45+ patients as compared to CD45− ALL patients (p = 0.0427, Fig. 4B). Here, ADAM6 is linked to acute lymphoblastic leukemia.